CytomX Therapeutics (CTMX) Enterprise Value (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Enterprise Value came in at -$346.7 million in Q1 2026, down 334.0% YoY from $148.2 million in Q1 2025, and down 152.97% on a QoQ basis from -$137.1 million in Q4 2025.
CytomX Therapeutics (CTMX) Enterprise Value (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Enterprise Value data on file, last reported at -$346.7 million in Q1 2026.
- Quarterly Enterprise Value fell 334.0% year-over-year to -$346.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$346.7 million (down 334.0% YoY) and the FY2025 annual result came in at -$137.1 million, down 36.2% from the prior year.
- Enterprise Value slipped to -$346.7 million in Q1 2026, from -$137.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$79.9 million in Q1 2025 to a low of -$346.7 million in Q1 2026.
- A 5-year average of -$176.7 million and a median of -$174.5 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value soared 46.84% — and 2026, when it sank 334.0%.
- Tracing CTMX's Enterprise Value over 5 years: stood at -$193.6 million in 2022, then increased by 9.88% to -$174.5 million in 2023, then soared by 42.34% to -$100.6 million in 2024, then slumped by 36.2% to -$137.1 million in 2025, then plunged by 152.97% to -$346.7 million in 2026.
- The last three Enterprise Value figures came in at -$346.7 million (Q1 2026), -$137.1 million (Q4 2025), and -$143.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -330.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -330.28 Mn |
| Mar 31, 2026 | -346.71 Mn |
| Dec 31, 2025 | -137.05 Mn |
| Sep 30, 2025 | -143.63 Mn |
| Jun 30, 2025 | -158.09 Mn |
| Mar 31, 2025 | -79.89 Mn |
| Dec 31, 2024 | -100.62 Mn |
| Sep 30, 2024 | -117.59 Mn |
| Jun 30, 2024 | -137.18 Mn |
| Mar 31, 2024 | -150.28 Mn |
| Dec 31, 2023 | -174.51 Mn |
| Sep 30, 2023 | -194.11 Mn |
| Jun 30, 2023 | -180.86 Mn |
| Mar 31, 2023 | -204.50 Mn |
| Dec 31, 2022 | -193.65 Mn |
| Sep 30, 2022 | -194.29 Mn |
| Jun 30, 2022 | -228.17 Mn |
| Mar 31, 2022 | -262.53 Mn |
| Dec 31, 2021 | -305.23 Mn |
| Sep 30, 2021 | -236.29 Mn |